STAT

DECEMBER 11, 2023

Oliver McGowan was 18 years old when he was hospitalized in England with recurrent seizures and pneumonia. He was autistic, and he and his parents had one specific request for the medical team: no antipsychotic medications. When he had taken them in the past, they made his seizures worse and had devastating effects on his mood. Despite the family’s vehement protests, doctors gave him an antipsychotic.

Medical Schools 358

Medical Schools Communication Hospitals 358

PharmaVoice

DECEMBER 11, 2023

Gilead Sciences’ SVP of global patient solutions discusses how she’s managing some of the world’s most complicated health issues and what’s next in HIV innovation.

130

130

STAT

DECEMBER 11, 2023

WASHINGTON — The House passed a relatively major health care package late Monday, an end-of-year victory after the same policies had to be yanked from consideration in September because they lacked bipartisan support. Though the package is unlikely to pass the Senate and become law as-is, its advancing through the House does make each included policy more attractive for a potential government funding deal, as lawmakers draw closer to the Jan. 19 deadline to fund the government and extend

Packaging 348

Packaging Hospitals 348

PharmaVoice

DECEMBER 11, 2023

Explore strategies for life sciences brands to simplify medication journeys for success through MedAdvisor Solutions’ THRIV™ platform, offering up to 5x more lift in adherence.

130

130

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

DECEMBER 11, 2023

During 2022, drugmakers substantially raised prices on eight widely used medicines without any new clinical evidence to justify the increases, leading patients and health insurers in the U.S. to spend an additional $1.2 billion last year, according to a new report. The drug for which spending increased the most due to a price increase was Humira, which is used to treat rheumatoid arthritis, plaque psoriasis, and other disorders.

Drug Pricing 341

Drug Pricing 341

PharmaVoice

DECEMBER 11, 2023

The FDA is now pushing companies to find the optimal dose early in development to minimize harm.

162

162

PharmaVoice

DECEMBER 11, 2023

How AstraZeneca is expanding its haematology footprint through the advancement of cutting-edge science in blood cancers.

130

130

STAT

DECEMBER 11, 2023

SAN DIEGO — For decades, the biotech industry has tried — and repeatedly failed — to develop new and effective painkillers without the addictive potential of opioids. But there’s reason to think that could begin to change soon. Vertex Pharmaceuticals is on the cusp of announcing results from late-stage trials of a drug that precisely blocks pain-sensing neurons from signaling the brain.

Diabetes 333

Diabetes Drug Development 333

The Pharmacist

DECEMBER 11, 2023

A report by UK public health officials has highlighted stark inequalities in the complications of flu and Covid infection related to deprivation and ethnicity. Hospital admission rates for flu and Covid are more than two times higher for people living in more deprived areas, the analysis by the UK Health Security Agency (UKHSA) has concluded. […] The post Covid and flu hospital admissions twice as high in deprived areas, UKHSA warns appeared first on The Pharmacist.

Hospitals 129

Hospitals Vaccines 129

STAT

DECEMBER 11, 2023

Vertex Pharmaceuticals made history Friday when it received regulatory approval for a medicine that could alter people’s DNA. While the company celebrated, its founder, Joshua Boger, looked on like a proud parent. Boger, 72, founded Vertex in 1989 and served in various roles until 2017. To this day, he lives next door to the company’s headquarters in Boston’s Seaport District, in a high-rise penthouse where he can quite literally look in on the biotech’s offices.

Labelling 315

Labelling 315

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

BioPharma Dive

DECEMBER 11, 2023

AbbVie’s blockbuster medicine topped a list of treatments that, combined, elevated U.S. healthcare spending by $1.3 billion in 2022, according to the price watchdog’s latest yearly report.

115

115

STAT

DECEMBER 11, 2023

One of the most prestigious names in medical publishing is going all in on artificial intelligence. The New England Journal of Medicine on Monday will launch NEJM AI , a monthly, online-only publication that will focus on evaluating applications of artificial intelligence in clinical medicine. The journal will also publish review articles, policy perspectives, and educational materials for physicians and computer scientists.

303

303

European Pharmaceutical Review

DECEMBER 11, 2023

Results from MaaT Pharma’s Early Access Program (EAP) for its microbiome-based therapy MaaT013, have demonstrated positive overall response and overall survival rates in European patients with graft-versus-host disease (GvHD). The findings were presented at the 2023 American Society of Hematology (ASH) Annual Meeting. MaaT013 is an off-the-shelf, pooled-donor, enema Microbiome Ecosystem Therapy TM.

Hospitals 115

Hospitals 115

STAT

DECEMBER 11, 2023

In its latest bid to police the pharmaceutical industry, the U.S. Federal Trade Commission sought to block Sanofi from licensing a Pompe disease treatment made by another drug company. And in response, Sanofi is ending the deal. Sanofi sought the rights to the medication from Maze Therapeutics, but the regulator argued the deal — valued at $775 million — would eliminate a “nascent competitor” that could, otherwise, challenge the monopoly Sanofi has in the market for P

284

284

Pharma Times

DECEMBER 11, 2023

New data highlights the inequalities in emergency hospital rates and vaccinations - News - PharmaTimes

Vaccines 139

Vaccines Hospitals 139

STAT

DECEMBER 11, 2023

Amid fears of superbugs, the sale of medically important antibiotics given to food-producing livestock rose by 4% overall in the U.S. in 2022, an increase that prompted advocates to complain that not enough is being done to thwart antibiotic resistance. In particular, the sale and distribution of tetracycline, which accounted for 65% of the medically important antibiotics given the livestock, increased by 4%, according to the latest annual report from the U.S.

280

280

Pharma Times

DECEMBER 11, 2023

Around 2,100 GP surgeries had enrolled into the digital service by the end of November - News - PharmaTimes

134

134

STAT

DECEMBER 11, 2023

AdvaMed named Peter Arduini, CEO of GE HealthCare, chair of its board of directors on Monday. The medical device lobby also announced the creation of a new division focused on policy issues for medical imaging technology. Arduini has been acting chair over the past few weeks, after former Johnson & Johnson MedTech CEO Ashley McEvoy stepped down.

255

255

Express Pharma

DECEMBER 11, 2023

The growing emphasis on a resilient supply chain in pharma and life sciences has brought the temperature-controlled supply chain, known as the cold chain, into the spotlight. The COVID-19 pandemic also highlighted the vital role of the cold chain in ensuring patient safety during vaccine distribution. And, with India’s vaccine, biopharma, and clinical trials market projected to grow in double-digits, there will be an increasing demand for efficient cold chain facilities.

Packaging 105

Packaging Vaccines 105

STAT

DECEMBER 11, 2023

WASHINGTON — An executive at insurance giant UnitedHealth Group is slated to be the next leader of the health insurance industry’s largest lobbying group, the group announced Monday. AHIP has selected Mike Tuffin, who’s currently UnitedHealth’s senior vice president for external affairs and head of U.S. government affairs, to be its next leader, after Matt Eyles announced his retirement from the group earlier this year after a five-year tenure.

241

241

Pharmaceutical Technology

DECEMBER 11, 2023

Trends in sustainability and quality assurance were key themes discussed at the recent CPHI Europe 2023 meeting, although the data reveals a lack of implementation of sustainable solutions.

105

105

STAT

DECEMBER 11, 2023

Dr. Laurie Glimcher learned early on from her father, a prominent physician-researcher, that success in science was built on a basic principle: Big discoveries require big risks. The younger Glimcher took that advice to heart. In the late 1990s at her Harvard immunology lab, Glimcher and her postdoctoral student began a series of experiments that colleagues deemed “crazy.

Hospitals 234

Hospitals 234

PharmExec

DECEMBER 11, 2023

Phase III trial to investigate novel individualized neoantigen therapy V940 (mRNA-4157) in combination with Keytruda (pembrolizumab) as an adjuvant treatment for patients with completely resected Stage II, IIIA, or IIIB non-small cell lung cancer.

105

105

STAT

DECEMBER 11, 2023

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because the usual routine of online meetings and deadlines has predictably returned. But what can you do? The world, such as it is, continues to spin. So time to give it a nudge in a better direction with a cup or three of stimulation.

Labelling 212

Labelling 212

The Pharmacist

DECEMBER 11, 2023

Heat-related deaths are estimated to increase by one and a half times in the 2030s, while mosquito-borne diseases are also likely to come to the UK in the ‘near future’. These are stark warnings featured in today’s UKHSA report on the effects of climate change – the first of its kind since 2012. Threats from […] The post Climate change likely to bring mosquito-borne diseases to UK, UKHSA warns appeared first on The Pharmacist.

Vaccines 104

Vaccines 104

STAT

DECEMBER 11, 2023

Understand how science, health policy, and medicine shape the world everyday. Sign up for our Morning Rounds newsletter here. This week on  The Readout LOUD  podcast, host Adam Feuerstein announced his first order of business if he ever becomes FDA commissioner: “Outlawing” FDA drug approval announcements on Fridays. Despite this position, he bravely covered the historic approval of the first CRISPR-based medicine last week.

209

209

BioPharma Dive

DECEMBER 11, 2023

Editas had the tall task Monday of convincing ASH attendees its gene therapy for sickle cell disease could improve on Casgevy and Lyfgenia.

115

115

STAT

DECEMBER 11, 2023

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Hello from ASH! Writing this Readout from a press room at the annual hematology confab here in San Diego. Today’s edition is chockfull of Vertex content, plus some extras from ASH and elsewhere.

Drug Pricing 172

Drug Pricing Drug Development 172

Express Pharma

DECEMBER 11, 2023

Zydus Worldwide DMCC, a wholly owned subsidiary of Zydus Lifesciences and Daewoong Pharmaceutical Co announced that they have entered into an exclusive licensing agreement to co-develop and commercialise Leuprolide Acetate for Depot Suspension (RLD: Lupron Depot, AbbVie) in six dosage strengths for the United States (US) market. Under the terms of the agreement, Zydus will assume full responsibility for the clinical development and commercialisation in the US market, and Daewoong will be respons

Dosage 100

Dosage 100

The Pharmacist

DECEMBER 11, 2023

Peterborough-based pharmacist Gareth Evans has been named Pharmacist of the Year at the General Practice Awards 2023. Mr Evans, community pharmacist at Wansford Pharmacy, was awarded the prestigious title at a ceremony held at Novotel London West following a year of achievement in helping patients with sleeping difficulties. Having established a patient-funded sleep apnea screening […] The post Pharmacist of the year named at General Practice Awards 2023 appeared first on The Pharmacist.

98

98

Express Pharma

DECEMBER 11, 2023

Wockhardt announced the completion of the pivotal Phase 3 pneumonia Study of its macrolide antibiotic Nafithromycin WCK 4873. Wockhardt NCE, WCK 4873 named as Nafithromycin was comparatively evaluated in multi-centre double blind Phase 3 pneumonia study employing the last-line respiratory antibiotic Moxifloxacin. The results of the study showed that an ultrashort course of three-day treatment with Nafithromycin is as effective as seven-day therapy with Moxifloxacin.

100

100

European Pharmaceutical Review

DECEMBER 11, 2023

The European Commission (EC) has approved the first frontline immuno-oncology treatment in the EU for mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. GSK’s Jemperli (dostarlimab) plus carboplatin-paclitaxel chemotherapy is indicated for these patients who are suitable for systemic therapy.

Chemotherapy 87

Chemotherapy 87

Express Pharma

DECEMBER 11, 2023

Dr Reddy’s Laboratories SA and Coya Therapeutics recently announced that they have entered into a development and license agreement for the development and commercialisation of COYA 302, an investigational combination therapy for the treatment of amyotrophic lateral sclerosis (ALS). Under the terms of the agreement, Coya has granted Dr Reddy’s an exclusive license to commercialise COYA 302, a proprietary co-pack kit containing combination of low dose IL-2 and CTLA-4 Ig (abatacept) in the U

99

99

pharmaphorum

DECEMBER 11, 2023

Predictive genetic testing offers the greatest promise and ethical challenge of our time Mike.

119

119

Express Pharma

DECEMBER 11, 2023

Bessemer Venture Partners, a leading global venture capital and private equity firm released its report focused on the sales and marketing stack of Indian pharma companies, analysing India’s burgeoning pharma market and the role of technology in further amplifying this growth. As per the report, the $50 billion Indian pharma market is expected to grow at ~8 per cent CAGR for the next five years and is poised for transformation.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies 98